Staquicini, Fernanda I.
Smith, Tracey L.
Tang, Fenny H. F.
Gelovani, Juri G.
Giordano, Ricardo J.
Libutti, Steven K.
Sidman, Richard L.
Cavenee, Webster K.
Arap, Wadih
Pasqualini, Renata http://orcid.org/0000-0002-4155-9324
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA122568, R01CA122568)
Gillson Longenbaugh Foundation
Article History
Received: 19 December 2018
Revised: 9 April 2019
Accepted: 27 April 2019
First Online: 27 May 2019
Compliance with ethical standards
:
: JGG, SKL, WA, and RP are founders of PhageNova Bio, which has licensed intellectual property related to the AAVP technology. RP is Chief Scientific Officer and a paid consultant for PhageNova Bio. JGG, WA, and RP are inventors on issued patents and pending patent applications related to AAVP technologies and are entitled to standard royalties if commercialization occurs. These arrangements are managed in accordance with established institutional conflict of interest policies. The remaining authors declare no conflicts of interest.